Альва, Джерси-Сити, часть 3: финал

Gus Alva, MD, shared that intranasal esketamine has potential to serve as a model for implementing treatments governed by a risk evaluation and mitigation strategy designed to safeguard patients. Patients receiving esketamine required supervision after dosing: "somebody needs to be under observation for 2 hours after the last dose that they've actually received," Alva said. Early adoption may be challenging because clinics were uncertain how they would be compensated for the observation period, and many anticipated financial losses under that model given their fiduciary responsibilities. Esketamine delivery exemplified the operational lessons clinics had to learn to apply when dispensing agents in real-world clinical settings. With time, clinics like Alva's had established approaches that allowed esketamine to be deployed while the clinic was reimbursed for the time used. ---------- 🔗 Read more: https://www.psychiatrictimes.com 📩 Subscribe for more: @PsychTimes 🌐 Visit us: https://www.psychiatrictimes.com ---------- Psychiatric Times is the No. 1 psychiatric publication in the US. Visit us at psychiatrictimes.com for the latest clinical news, expert perspectives, and CME opportunities. #psychiatry #psychiatrictimes #psychedelicscience #mooddisorders #depression